Cargando…
CIDP: Analysis of Immunomarkers During COVID-19 mRNA-Vaccination and IVIg-Immunomodulation: An Exploratory Study
Availability of COVID-19 mRNA vaccine for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with intravenous immunoglobulin (IVIg) raises the question of whether COVID-19 mRNA vaccine influences disease activity or IVIg-mediated immunomodulation in CIDP. In this explorat...
Autores principales: | Svačina, Martin K. R., Meißner, Anika, Schweitzer, Finja, Sprenger-Svačina, Alina, Klein, Ines, Wüstenberg, Hauke, Kohle, Felix, Walter, Helene L., Schroeter, Michael, Lehmann, Helmar C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018581/ https://www.ncbi.nlm.nih.gov/pubmed/36929282 http://dx.doi.org/10.1007/s11481-023-10058-x |
Ejemplares similares
-
Could symptom overlap of COVID-19 and Guillain–Barré syndrome mask an epidemiological association?
por: Svačina, Martin K. R., et al.
Publicado: (2021) -
Repurposing MS immunotherapies for CIDP and other autoimmune
neuropathies: unfulfilled promise or efficient strategy?
por: Kohle, Felix, et al.
Publicado: (2023) -
CIDP prognosis in patients with IVIG treatment‐related fluctuations
por: Cook, Melissa, et al.
Publicado: (2022) -
MRI biomarkers of proximal nerve injury in CIDP
por: Lichtenstein, Thorsten, et al.
Publicado: (2017) -
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies
por: Merkies, Ingemar S.J., et al.
Publicado: (2019)